Openbookopenbook
Equity
StockUS listing USSTAANASDAQHealthcareValue Trap

STAAR Surgical Company(STAA) Stock Analysis | Healthcare

USD --+0.00%
Reward40Moderate
Risk38Moderate
75%Data
Thin 1% profit margin · Revenue growing 111% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 1.07Bn
Reward Ratingⓘ40 Moderate reward assessment · 75% data coverage
Bottom 10% of stocksView factors
Risk Ratingⓘ38 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on STAA to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is STAAR Surgical Company?

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye.

AI Brief Pro

The brief on STAAR Surgical Company

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is STAAR Surgical Company?

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.07B, and a P/E ratio of 265.9x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (40)

Similar stocks to compare

A short list of Medical Instruments & Supplies names that are close enough in size to make side-by-side comparison useful.

TDVXFSmall Cap / 992M market cap
Tobii Dynavox AB (publ)
Compare
NKNSFSmall Cap / 1.2B market cap
NKNSF
Compare
TPGVFSmall Cap / 1.3B market cap
Top Glove Corporation Bhd
Compare
Company Information
SectorHealthcare
IndustryMedical Instruments & Supplies
Market Cap1.07B
P/E Ratio265.875
Dividend YieldN/A
Beta1.177
Insider Activity
12M windowMixed
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
0
3670,213 shares
$12.3M
9-12months
0
71,934,138 shares
$50.5M
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.